DunningKruger
Explorer
Peppy’s hosts a large number of LL-37 studies: a few encouraging, a few alarming, and a great many with thin reporting—dosing details absent, methods murky, or designs that do not hold up. More can be found through Google Scholar, though sorting signal from noise there takes patience and careful reading.
From my own experience, I added LL-37 to a prevention stack not long ago after spending time near someone who was obviously unwell. For 10 days I took 200 mcg per day. It did not act as an impenetrable barrier—I spent a couple of days feeling slightly “off”—yet the illness never developed into anything more.
What I did not expect was that by the end of that run my rosacea had almost vanished. That was the outcome I had hoped for from GHK but never achieved. Later I also tried it topically, mixed into a tallow balm, even after coming across a study suggesting LL-37 might cause rosacea-like lesions that do not reverse. To me that study seemed badly put together, so I did not treat it as decisive on its own.
Nobody should start LL-37 before working through multiple studies and grasping the risks being proposed, since the theoretical drawbacks are far from minor. For my part, I will keep it available as a single component within a wider prevention approach, together with mAbs and other better-supported choices.
